Operates a chain of multi-specialty hospitals across North India, with facilities spanning Delhi/NCR, Haryana, Punjab, Rajasthan, Uttar Pradesh and Uttarakhand. Served 8.7 lakh patients in FY26 — comprising 95,525 in-patient admissions and 7.78 lakh out-patient visits — with a network-wide occupancy of 64.1%. Revenue comes from hospital services across specialties; high-acuity work (cardiology, oncology, neurology, orthopaedics, urology, gastroenterology) contributed 56.9% of FY26 revenue, with specific procedures including 150+ kidney transplants, 4,700+ PTCA, 1,200+ cardio-vascular surgeries and 2,600+ robot-assisted joint replacements. Roughly 80% of payer mix comes from government insurance schemes (CGHS and others); a CGHS rate hike of 12-15% is expected to lift FY27 revenue by 7-7.5%. Costs are dominated by other operating expenses (36.7% of revenue) and employee costs (19.3%); materials run at 17.6%. The group is expanding toward 5,460 beds by March 2028 via greenfield projects (Panchkula, Kanpur, Gorakhpur, Rohtak) and acquisitions, including The Medicity Hospital in Rudrapur (330 beds, INR 177 crore deal). AR · MarketPing reader · 2026-08-02
Revenue streams, as the annual report describes them. In-patient high-acuity specialties (57%), Other in-patient and out-patient hospital services, Government insurance scheme patients, Private insurance and walk-in patients. Asset-heavy, capacity-expanding hospital chain with high government-payor exposure and a large greenfield-plus-acquisition build-out plan.
| ₹ crore · consolidated | FY26 |
|---|---|
| Revenue | 1,679 |
| EBITDA (ex other income) | 444 |
| margin % | 26.5 |
| Owners' profit | 258 |
| EPS, as reported (₹) | 6.87 |
| ROE % · ROCE % | 13.0 · 18.1 |
| Debt / equity (x) | 0.11 |
| Cash from operations | 329 |
| Capex | (120) |
| ₹ crore | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|
| Revenue | 410 | 460 | 476 |
| Profit before tax | 78 | 103 | 105 |
| Net profit | 53 | 77 | 89 |
| EPS (₹) | 1.35 | 1.78 | 2.05 |
| Company | M.cap ₹ cr | P/E | P/B | EV/EBITDA | ROE % | ROCE % | Rev CAGR 5y % | EBITDA m. % |
|---|---|---|---|---|---|---|---|---|
| APOLLO HOSPITALS ENTER. L | 1,27,062 | 60.8 | 12.74 | 33.5 | 20.1 | 16.6 | 19.0 | 16.2 |
| MAX HEALTHCARE INS LTD | 1,00,993 | 69.2 | 9.40 | 44.0 | 13.4 | 11.1 | 27.3 | 27.0 |
| FORTIS HEALTHCARE LTD | 67,025 | 64.0 | 6.59 | 32.9 | 10.5 | 9.7 | 17.8 | 22.0 |
| ASTER DM QUALITY CARE LTD | 39,689 | 124.0 | 8.21 | 40.4 | 8.8 | 8.5 | (11.6) | 14.3 |
| GLOBAL HEALTH LIMITED | 38,972 | 70.0 | 9.78 | 39.4 | 13.9 | 13.5 | — | 23.7 |
| NARAYANA HRUDAYALAYA LTD. | 38,213 | 46.5 | 8.42 | 25.4 | 17.8 | 9.2 | 25.0 | 18.8 |
| KRISHNA INST OF MED SCI L | 32,235 | 150.5 | 12.60 | 43.4 | 9.5 |
| Date · filing | Category | Importance | 1-day % | 5-day % |
|---|---|---|---|---|
| 8 Sept 2026 · Park Medi World incorporates wholly owned Prayagraj hospital subsidiary | strategic transactions | medium | — | — |
| 8 Sept 2026 · Park Medi World re-files Q1 FY27 results in readable format; no change in figures | compliance | low | — | — |
| 5 Sept 2026 · Park Medi World to attend four investor conferences in September 2026 | investor communications | low | — | — |
| 4 Sept 2026 · Postal Ballot: Shareholders approve amendment to IPO proceeds objects | board shareholder meetings | medium | — | — |
| 31 Aug 2026 · Park Medi World sets up wholly owned subsidiary for Prayagraj hospital | strategic transactions | high | — | — |
| 31 Aug 2026 · Board approves wholly-owned subsidiary for Prayagraj hospital project | strategic transactions | high | — | — |
| 29 Aug 2026 · Newspaper ad for 15th AGM notice with e-voting and dispatch details | compliance | minimal | — | — |
| 28 Aug 2026 · Annual Report and AGM notice for FY 2025-26 shared with shareholders | board shareholder meetings | low | — | — |
| 28 Aug 2026 · Annual Report FY25-26 and AGM Notice - Park Medi World | board shareholder meetings | low | — | — |
| 28 Aug 2026 · 15th AGM scheduled on September 22, 2026 via video conference | board shareholder meetings | low | — | — |
| Where a broker report shows | This document shows | Why |
|---|---|---|
| 5.1 |
| 24.0 |
| 20.3 |
| DR AGARWALS HEALTH CARE L | 16,043 | 107.9 | 7.57 | 26.2 | 7.9 | 7.1 | — | 28.8 |
| Metric | Company | Group median | Rank | Better than |
|---|---|---|---|---|
| P/E (TTM) | 54.0 | 47.3 | 21 of 30 | 31% |
| P/B | 5.8 | 6.2 | 11 of 24 | 57% |
| ROCE | 15.5 | 10.9 | 4 of 30 | 90% |
| ROE | 13.0 | 11.8 | 10 of 24 | 61% |
| Debt / Equity | 0.1 | 0.2 | 8 of 24 | 70% |
| EBITDA margin | 28.1 | 22.0 | 6 of 24 | 78% |
| Market cap | 12090 | 2415 | 10 of 30 | 69% |
| A rating (BUY / ADD / REDUCE / SELL) |
| A state: the latest filed quarter and the measured reactions |
| an event is a fact; a rating is an opinion that requires SEBI RA registration |
| A target price and upside | The current price and the multiples against the group | a target is a forecast; a multiple is a measurement |
| Estimate years marked E | More audited years; no estimates | MarketPing publishes no forecasts — your own model lives on the Models page |
This document is a statistical summary of publicly filed information and market data, prepared by software from primary sources: SEBI results XBRL filed with BSE and NSE, LODR disclosures, shareholding patterns, exchange price data. It contains no research recommendation, no price target and no opinion on the merits of any security, and is not a research report within the meaning of the SEBI (Research Analysts) Regulations, 2014, Regulation 2(1)(w)(vii). Financial statements are as filed (consolidated where the company files consolidated results). Ratios are computed over filed lines. Where a figure is unavailable the table shows a dash rather than an estimate. The business brief is written by MarketPing's reader from the annual report and checked against it; no figure in a table was generated by a model. Nothing here constitutes investment advice, an offer or a solicitation; readers should consult a SEBI-registered adviser before acting. MarketPing is not a SEBI-registered intermediary.
